Clinical trials
Metastatic Colorectal Carcinoma clinical trials
Below are recruiting metastatic colorectal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 223 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT07159048Recruiting
Heat therapy for liver tumors
This trial tests a heat-based treatment for liver cancer tumors that uses multiple methods to destroy cancer cells. It may help people with liver tumors that haven't spread and who are healthy enough for treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06642844RecruitingPhase 3
Bevacizumab dose adjustment for colorectal cancer
This trial tests whether adjusting the dose of bevacizumab based on your blood levels can improve first-line treatment for metastatic colorectal cancer that can't be removed with surgery.
BesançonAges 18–99 - NCT06321081RecruitingPhase 2
Rechallenge combo for metastatic colorectal cancer
This trial tests a combination of three drugs (cetuximab, irinotecan, and envafolimab) as a ‘rechallenge’ – meaning if you had good results with cetuximab or irinotecan before, trying them again with a new drug might help shrink or control your cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03001362Recruiting
Wait-and-see treatment for people with rectal cancer
This study tests a “wait-and-see” approach instead of immediate surgery for certain rectal cancers, aiming to avoid unnecessary operations. It may help people who are medically able to stay under close monitoring and only have surgery if needed.
Montreal, QuebecAges 18–90 - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05229003RecruitingPhase 2
Irinotecan, anlotinib, and pembrolizumab-like drug for advanced colon cancer
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05310643RecruitingPhase 2
Nivolumab and ipilimumab for bowel cancer resistant to anti-PD1
This Phase 2 study tests two immunotherapy medicines (nivolumab and ipilimumab) in people with metastatic colorectal cancer that has not responded to anti-PD1 treatment. It focuses on tumors with mismatch repair problems (dMMR) and/or high microsatellite instability (MSI).
BesançonAges 18 years+ - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT05787197Recruiting
Blood test to guide treatment after colon cancer liver surgery
This trial studies a blood test (called ctDNA) in people with colon cancer that has spread to the liver and is being removed with curative surgery. The goal is to see how the blood test can help with planning and improving treatment after surgery.
BesançonAges 18 years+ - NCT05970302RecruitingPhase 2
XELOX, bevacizumab, and immunotherapy for metastatic colon cancer
This Phase 2 trial studies a combination treatment (XELOX plus bevacizumab plus an immunotherapy drug) for people with metastatic colon cancer that has certain lab features (MSS/pMMR and RAS-mutated). It aims to see how well the treatment works as a first treatment when the cancer cannot be removed with surgery.
BeijingAges 18 years+ - NCT06077591Recruiting
Genetic and organoid testing to guide cancer treatment
This trial uses advanced testing (genetic sequencing and lab-grown tumor models) to find the best treatment for people with advanced solid tumors that haven't responded to at least one standard treatment. The goal is to personalize therapy based on your tumor's unique features.
Hong Kong, N.T.Ages 18–100 - NCT06202001RecruitingPhase 1/Phase 2
Three-drug combo for metastatic colorectal cancer as second treatment
This trial tests a combination of three drugs (irinotecan, TAS-102, and bevacizumab) for people with metastatic colorectal cancer that has already been treated with oxaliplatin-based chemotherapy. The goal is to see if this three-drug combination works better as a second treatment option.
BeijingAges 18–70 - NCT06551207Recruiting
New drug combo with radiation for advanced MSS colon cancer
This trial tests a new combination—an immunotherapy drug (cadonilimab) plus a targeted anti-angiogenesis pill (fruquintinib) and focused radiation (SBRT)—for people with MSS colorectal cancer that has progressed after at least two prior treatments. The goal is to see if this triple approach can help shrink or control the cancer better than standard options.
Wuhan, HubeiAges 18–75 - NCT06850103RecruitingPhase 2
Chemo, radiation, and immunotherapy for advanced rectal cancer that has spread a little
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (serplulimab) for people with rectal cancer that has spread to just a few spots in the body (no more than 5 tumors in up to 2 locations). It aims to see if this approach is safe and effective.
Hangzhou, ZhejiangAges 18–75 - NCT06922383RecruitingPhase 1/Phase 2
Study of arfolitixorin in advanced colorectal cancer
This study tests a new drug called arfolitixorin given with standard chemotherapy (FOLFOX or FOLFIRI) plus a targeted therapy for people with advanced colorectal cancer that has spread. It may help the chemotherapy work better.
BerlinAges 18 years+ - NCT06978400RecruitingPhase 2
Targeted therapy plus chemo for BRAF mutant colorectal cancer
This trial tests a combination of targeted therapy (dabrafenib) and two other drugs (cetuximab or panitumumab) plus standard chemotherapy (FOLFOX) as a first treatment for people with a specific type of metastatic colorectal cancer that has a BRAF V600E mutation and is microsatellite stable.
MoscowAges 18 years+ - NCT06991465RecruitingPhase 2
Organ preservation trial for rectal cancer using shorter radiation
This trial tests a shorter course of radiation to the pelvis to treat rectal cancer, with the goal of avoiding surgery and preserving the rectum. It may be an option for people with advanced rectal cancer that has not spread to other organs.
Montreal, QuebecAges 18–90 - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+ - NCT07436078Recruiting
Genetic testing study for African American cancer survivors
This study offers genetic testing and counseling to African American cancer survivors. It aims to see if a culturally tailored approach helps more people understand their cancer risk and get the testing they need.
Detroit, MichiganAges 20–79 - NCT07540572RecruitingPhase 1
Testing IDE574 safety and effectiveness in advanced solid tumors
This early-stage trial tests a new drug called IDE574 to see if it is safe and effective in treating advanced cancers that have spread or stopped responding to standard treatments. The trial focuses mainly on hormone-receptor positive breast cancer, but also includes lung, prostate, and colorectal cancers.
Plantation, FloridaAges 18–99 - NCT07646106RecruitingPhase 1
Testing THE-0504 in Advanced Solid Tumors
This Phase 1 trial tests a new drug called THE-0504 in patients with advanced solid tumors (like lung, colon, pancreas, stomach, or breast cancer) that have not responded to standard treatments. The study aims to find the right dose and understand how well and safely the drug works.
Rome, LazioAges 18 years+
Hear when a new Metastatic Colorectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic colorectal carcinoma?
- Yes. Clin2 currently lists 223 recruiting metastatic colorectal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic colorectal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic colorectal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.